France's Health Minister, Roselyne Bachelot, has ruled out the adoption of the UK's National Institute for Health and Clinical Excellence (NICE) drug reimbursement model by the French health spending watchdog, the HAS. The latter's role has been expanded, with a more selective reimbursement in the future. Mrs Bachelot told the Parliament: "I am not in favor of integrating, as exemplified by the NICE, the notion of quality-adjusted life-years into the indicators of medical efficacy. That does not accord with the culture from which the HAS must be inspired."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze